MEI Pharma, Inc. (MEIP)

Oncology Corporate Profile

Stock Performance

1.5800
0.0000

HQ Location

11975 El Camino Real, Suite 101
San Diego, CA 92130

Company Description

MEI Pharma (formerly Marshall Edwards Inc.) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, and two isoflavone-based drug candidates, ME-143 and ME-344.

Website: http://www.meipharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
pracinostat (+ azacitidine)HDAC inhibitor (oral)Acute Myelogenous Leukemia (AML)IIHelsinn
ME-344 (+ bevacizumab) mitochondrial inhibitorBreast cancer (HER2+)II
pracinostat (+ azacitidine)HDAC inhibitor (oral)Myelodysplastic Syndrome (MDS)II
pracinostat (+ ruxolitnib)HDAC inhibitor (oral)MyelofibrosisII
ME-401PI3K Delta InhibitorChronic Lymphocytic Leukemia (CLL)I
ME-401P13K delta inhibitorFollicular LymphomaI
phenoxodiolNADH oxidase inhibitorVarious cancer typesINovogen
ME-143NADH oxidase inhibitorVarious cancer typesI
PWT143P13K delta inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source


http://www.meipharma.com/

Recent News Headlines

MEI Pharma to Present at Oppenheimer Healthcare Conference

3/14/2017 01:00 pm

[PR Newswire] - SAN DIEGO, March 14, 2017 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer Healthcare Conference on Tuesday, March 21, 2017 at 9:10 a.m. Eastern time from the Westin New York Grand Central. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

MEI PHARMA, INC. Financials

2/11/2017 06:00 pm

Post Earnings Coverage as Summit Therapeutics Q3 Net Loss Narrowed; Entered into Agreement with Sarepta

12/27/2016 01:01 pm

[Accesswire] - Upcoming AWS Coverage on MEI Pharma Post-Earnings Results LONDON, UK / ACCESSWIRE / December 27, 2016 / Active Wall St. announces its post-earnings coverage on Summit Therapeutics PLC (NASDAQ: SMMT). The ...

Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

12/5/2016 01:00 pm

[PR Newswire] - LUGANO, Switzerland, and SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced final results from a Phase 2 clinical study of the investigational drug candidate Pracinostat and azacitidine in elderly patients with acute myeloid leukemia (AML) who were not eligible for induction chemotherapy, including evidence of prolongation of survival in the overall population and across a number of patient subgroups. In an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Saturday, Dr. Guillermo Garcia-Manero, MD Anderson Cancer Center, principal investigator of the study, reported a median overall survival of 19.1 (95%CI: 10.7-26.5) months, one-year survival of 62% and a complete response (CR) rate of 42%.

MEI Pharma to Host Annual Meeting of Stockholders

11/17/2016 02:00 pm

[PR Newswire] - SAN DIEGO, Nov. 17, 2016 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Pacific time on Thursday, December 1, 2016, at the Company's headquarters, located at 11975 El Camino Real, Suite 101, San Diego, CA 92130. Stockholders of record at the close of business on October 5, 2016 are entitled to receive notice of and vote at the Annual Meeting. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

MEI Pharma Reports First Quarter Fiscal Year 2017 Results

11/9/2016 01:03 pm

[PR Newswire] - SAN DIEGO, Nov. 9, 2016 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its first quarter ...

MEI Pharma Reports First Quarter Fiscal Year 2017 Results

11/9/2016 01:03 pm

[at noodls] - SAN DIEGO, Nov. 9, 2016/PRNewswire / -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its first quarter ...

MEI Pharma to Present at Stifel Healthcare Conference

11/7/2016 02:00 pm

[PR Newswire] - SAN DIEGO, Nov. 7, 2016 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference on Tuesday, November 15, 2016 at 3:45 p.m. Eastern time from the Lotte New York Palace Hotel. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.

Blog Coverage MEI Pharma and Helsinn Group Announced Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia

11/4/2016 12:01 pm

[Accesswire] - Upcoming AWS Coverage on Depomed Post-Earnings Results LONDON, UK / ACCESSWIRE / November 4, 2016 / Active Wall St. blog coverage looks at the headline from MEI Pharma, Inc. (NASDAQ: MEIP ) and Swiss pharmaceutical ...

Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting

11/3/2016 01:00 pm

[PR Newswire] - LUGANO, Switzerland and SAN DIEGO, Nov. 3, 2016 /PRNewswire/ -- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that long-term survival and response data from a Phase II clinical study of Pracinostat and azacitidine in older patients with acute myeloid leukemia have been selected for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego on December 3-6, 2016. An abstract of the presentation was published today on the ASH website at www.hematology.org.

MEI Pharma Reports Fiscal Year 2016 Results

9/6/2016 01:01 pm

[at noodls] - SAN DIEGO, Sept. 6, 2016/PRNewswire / -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its fiscal year ...

MEI Pharma Reports Fiscal Year 2016 Results

9/6/2016 12:03 pm

[PR Newswire] - SAN DIEGO, Sept. 6, 2016 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today reported results for its fiscal year ended June 30, 2016. "All of our efforts over the past year combined to set the stage for what has already been an exciting start to the new fiscal year, highlighted by Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and a global strategic partnership for Pracinostat," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "We are proud to have a strong commercial partner in Helsinn now on board.

MEI Pharma to Present at Wedbush PacGrow Healthcare Conference

8/10/2016 01:00 pm

[PR Newswire] - SAN DIEGO, Aug. 10, 2016 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 8:00 a.m. Eastern time from Le Parker Meridien in New York. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.